Search Results

You are looking at 11 - 20 of 151 items for :

  • "renal cell carcinoma" x
Clear All
Full access

David Y. T. Chen and Robert G. Uzzo

Edited by Kerrin G. Robinson

: casting doubt on the efficacy of early intervention . Urology 2001 ; 57 : 1013 – 1015 . 3 Hollenbeck BK Taub DA Miller DC . National utilization trends of partial nephrectomy for renal cell carcinoma: a case of underutilization? Urology

Full access

Robert Torrey, Philippe E. Spiess, Sumanta K. Pal and David Josephson

Historically, renal cell carcinoma (RCC) has been a formidable cancer with limited responses to both radiation and systemic management. Currently, surgery offers the only real chance of cure for patients with cancer localized to the kidney and

Full access

Eric Jonasch

Over the past decade, a number of new therapies have been approved for the treatment of renal cell carcinoma (RCC; Figure 1 ). Most treatments are driven by clear cell histology, which represents 70% to 75% of all RCCs. Eric Jonasch, MD

Full access

Andre P. Fay, Guillermo de Velasco, Thai H. Ho, Eliezer M. Van Allen, Bradley Murray, Laurence Albiges, Sabina Signoretti, A. Ari Hakimi, Melissa L. Stanton, Joaquim Bellmunt, David F. McDermott, Michael B. Atkins, Levi A. Garraway, David J. Kwiatkowski and Toni K. Choueiri

Recurrent molecular aberrations at the epigenetic, DNA, RNA, and protein levels have been identified in clear cell renal cell carcinoma (ccRCC). 1 Common emerging themes have evolved, including dysregulation of the von Hippel-Lindau ( VHL ) gene

Full access

James Brugarolas

A significant challenge in oncology is the identification of predictive biomarkers of therapeutic benefit. The article in this issue by Fay et al (page 820 ) illustrates this issue in renal cell carcinoma (RCC). The challenge encompasses all RCC

Full access

Eric Jonasch

replace current options in the upfront metastatic setting for clear cell renal cell carcinoma (ccRCC), based on recently reported pivotal trials. Some of these new regimens are not yet incorporated into the NCCN Guidelines, but are expected to be soon

Full access

Tarek Haykal, Babikir Kheiri, Varun Samji, Yazan Zayed, Ragheed Al-Dulaimi, Inderdeep Gakhal, Areeg Bala, Jason Sotzen, Ahmed Abdalla and Ghassan Bachuwa

Background: Metastatic clear-cell renal cell carcinoma (RCC) is largely incurable, and its treatment remains challenging. Sunitinib, a tyrosine kinase inhibitor, is one of the current standard-of-care options for treatment-naïve patients with

Full access

Eric Jonasch

“It is a very exciting time in renal cell carcinoma, with new treatments. Most of which are for clear cell carcinoma,” said Eric Jonasch, MD, Professor, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer

Full access

Angela Pecoraro, Giuseppe Rosiello, Stefano Luzzago, Marina Deuker, Franciska Stolzenbach, Zhe Tian, Shahrokh F. Shariat, Fred Saad, Alberto Briganti, Anil Kapoor, Cristian Fiori, Francesco Porpiglia and Pierre I. Karakiewicz

data can provide further detail regarding the distribution of patient and renal cell carcinoma (RCC) characteristics within this special patient group. Based on these considerations, we reexamined patients with RCC with T1a 0- to 2-cm renal tumors to

Full access

Toni K. Choueiri and Robert J. Motzer

Targeted therapies have changed the landscape of metastatic renal cell carcinoma (mRCC), with a current median survival of approximately 30 months reported in contemporary trials, representing a drastic improvement over the 12- to 13-month overall